Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration and loss of function of neurons in the central nervous system (brain and spinal cord) and, seldom, the peripheral nervous system. Cognitive ability, motor control, and other neurological processes gradually deteriorate as a result of these illnesses, which largely impact the structure and function of the brain. According to estimates, seven million new instances of neurodegenerative illnesses are recorded annually worldwide as of September 2022. Biomarkers are indicators that can be used to determine a disease’s presence, progression, or severity. It is essential for early diagnosis, monitoring disease development, and assessing the efficacy of treatment interventions in the setting of neurodegenerative illnesses.
Amyloid-beta and Tau Proteins in Alzheimer’s, Alpha-Synuclein in Parkinson’s disease, Neurofilament Light Chain (NfL) in Alzheimer’s, Parkinson’s, and Multiple sclerosis, etc. are some of the biomarkers that help in monitoring disease progression and treatment response. In addition, Cerebrospinal fluid biomarkers and genetic biomarkers aid in the diagnosis and help identify individuals at risk or confirm a genetic cause for neurodegenerative diseases.
The conference on neurodegenerative diseases — Biomarkers and therapeutic targets aims to explore and discuss the latest advancements in understanding, detecting, and treating various neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and Amyotrophic lateral sclerosis characterized by progressive degeneration of neurons leading to cognitive decline, motor dysfunction, and other debilitating symptoms. The focus of the conference revolves around two primary aspects biomarkers and targeted therapy. Molecular, genetic, imaging or biochemical markers provide valuable insights into the presence, progression, and characteristics of neurodegenerative diseases and help in accurate diagnosis, targeted therapy, and monitoring of disease progression.
The conference also aims to delve into the latest research on identifying and utilizing biomarkers for neurodegenerative diseases. Additionally, the conference focuses on targeted therapy which involves developing treatments that specifically target the underlying causes or pathological processes of neurodegenerative diseases. The traditional approach of symptomatic management is being augmented by the development of novel therapeutic strategies that aim at modifying or halting disease progression. Knowledge of the interventions targeting aberrant proteins, inflammation, mitochondrial dysfunction, and other mechanisms implicated in neurodegeneration is the conference’s potential outcome.
The purpose of the conference is to bring together researchers, clinicians, and experts from various disciplines to share their knowledge, present cutting-edge research findings, and foster collaborations in the field of neurodegenerative diseases by discussing biomarkers and targeted therapies. The conference aims to promote a deeper understanding of these diseases and explore innovative patient outcomes to enhance the quality of life and potentially find ways to prevent or cure neurodegenerative diseases in the future.